|
|||||
|
|
Anti-PD-1 antibody camrelizumab plus doxorubicin showed durable response in pulmonary sarcomatoid carcinoma: Case report and literature review |
|
| Authors: | Fengwei Kong BSc Weimin Wang MD Longbo Gong MD Wenbin Wu PhD Yuanyuan Liu PhD |
| Affiliation: | 1. Department of General Surgery, Xuzhou Infectious Disease Hospital, Xuzhou, Jiangsu, People’s Republic of China;2. Department of Respiratory and Critical Care Medicine, Xuzhou Central Hospital, Xuzhou, People’s Republic of China |
| Abstract: | |
| Keywords: | camrelizumab (SHR-1210) immune checkpoint inhibitors immunotherapy programmed cell death ligand 1 (PD-L1) programmed cell death protein 1 (PD-1) sarcomatoid carcinoma |